• Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial
• Treatment with EPA gastro-resistant capsules vs. standard care
• 28-day treatment period
• Primary outcome of time to treatment failure i.e. need for additional therapy, intubation, transfer to ICU, or death
• Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020)